Expression and Regulation of CacyBP/SIP in Chronic Lymphocytic Leukemia Cell Balances of Cell Proliferation with Apoptosis

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2015 Nov 26

PMID 26603518

Citations 7

Authors

Chunling Fu

Yan Wan

Hengliang Shi

Yanqing Gong

Qingyun Wu

Yao Yao

Mingshan Niu

Zhenyu Li

Kailin Xu

Affiliations

Soon will be listed here.

Abstract

Purpose: Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, with incidence in Chinese populations also increasing. CLL involves an accumulation of abnormal B cells which result in dysregulation of cell proliferation and apoptosis rates. The calcyclin-binding protein/Siah-1-interacting protein (CacyBP/SIP) plays a pivotal role in tumorigenicity and cell apoptosis. Here, we investigated the function of CacyBP/SIP in CLL cell proliferation and apoptosis.

Methods: CacyBP/SIP expression levels were measured in peripheral blood mononuclear cells from 23 Chinese CLL patients and three healthy donors by western blotting. Correlation analysis was performed to assess associations between CacyBP/SIP expression and clinical stage, chromosome abnormalities and zeta-chain-associated protein kinase 70 (ZAP-70) expression. We silenced CacyBP/SIP expression in MEC-1 cells using a lentivirus system and analyzed cell vitality, cell cycle and tumorigenicity. Apoptosis was also analyzed following the upregulation of CacyBP/SIP expression in MEC-1 cells.

Results: Downregulation of CacyBP/SIP expression in CLL patients was negatively correlated with CLL clinical stage, but not with patient sex, age, del(13q14) or del(17q-) presence, or ZAP-70 expression. CacyBP/SIP silencing significantly enhanced cell proliferation and tumorigenicity. CacyBP/SIP silencing promoted accumulation of cells in S phase by upregulation of β-catenin, cyclin D1 and cyclin E, and downregulation of p21. Moreover, CacyBP/SIP overexpression facilitated CLL apoptosis through the activation of pro-caspase-3.

Conclusion: CacyBP/SIP is a useful indicator of CLL disease processes and plays an important role in sustaining the balance of cell proliferation and apoptosis.

Citing Articles

Pan-analysis reveals CACYBP to be a novel prognostic and predictive marker for multiple cancers.

Mo B, Luo B, Wu Y Am J Transl Res. 2024; 16(1):12-26.

PMID: 38322570 PMC: 10839390.

The multifaceted interactions between Newcastle disease virus proteins and host proteins: a systematic review.

Lu X, Wang X, Liu X, Liu X Virulence. 2024; 15(1):2299182.

PMID: 38193514 PMC: 10793697. DOI: 10.1080/21505594.2023.2299182.

Protective effects of calcyclin-binding protein against pulmonary vascular remodeling in flow-associated pulmonary arterial hypertension.

Zhou J, Li F, Yang Y Respir Res. 2022; 23(1):223.

PMID: 36042446 PMC: 9429705. DOI: 10.1186/s12931-022-02137-z.

Downregulation of CacyBP by CRISPR/dCas9-KRAB Prevents Bladder Cancer Progression.

Zheng H, Chen C Front Mol Biosci. 2021; 8:692941.

PMID: 34179100 PMC: 8226165. DOI: 10.3389/fmolb.2021.692941.

CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma.

Zhao M, Zhang R, Qi D, Chen H, Zhang G Exp Ther Med. 2020; 20(2):1397-1404.

PMID: 32742374 PMC: 7388306. DOI: 10.3892/etm.2020.8843.

References

Sun S, Ning X, Liu J, Liu L, Chen Y, Han S . Overexpressed CacyBP/SIP leads to the suppression of growth in renal cell carcinoma. Biochem Biophys Res Commun. 2007; 356(4):864-71. DOI: 10.1016/j.bbrc.2007.03.080. View

Wickremasinghe R, Prentice A, Steele A . p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies. Leukemia. 2011; 25(9):1400-7. DOI: 10.1038/leu.2011.103. View

Matsuzawa S, Reed J . Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell. 2001; 7(5):915-26. DOI: 10.1016/s1097-2765(01)00242-8. View

Xia Z, Dai M, Magoulas C, Broxmeyer H, Lu L . Differentially expressed genes during in vitro differentiation of murine embryonic stem cells transduced with a human erythropoietin receptor cDNA. J Hematother Stem Cell Res. 2000; 9(5):651-8. DOI: 10.1089/15258160050196696. View

Chen X, Han G, Zhai H, Zhang F, Wang J, Li X . Expression and clinical significance of CacyBP/SIP in pancreatic cancer. Pancreatology. 2008; 8(4-5):470-7. DOI: 10.1159/000151774. View

Halina A, Artur P, Barbara M, Joanna S, Anna D . Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Folia Histochem Cytobiol. 2011; 48(4):534-41. DOI: 10.2478/v10042-010-0048-5. View

Sainz-Perez A, Gary-Gouy H, Gaudin F, Maarof G, Marfaing-Koka A, de Revel T . IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol. 2008; 181(9):6051-60. DOI: 10.4049/jimmunol.181.9.6051. View

Filipek A . S100A6 and CacyBP/SIP - two proteins discovered in ehrlich ascites tumor cells that are potentially involved in the degradation of beta-catenin. Chemotherapy. 2005; 52(1):32-4. DOI: 10.1159/000090240. View

Lowy A, Clements W, Bishop J, Kong L, Bonney T, Sisco K . beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. Cancer Res. 2006; 66(9):4734-41. DOI: 10.1158/0008-5472.CAN-05-4268. View

10.

Pekarsky Y, Zanesi N, Croce C . Molecular basis of CLL. Semin Cancer Biol. 2010; 20(6):370-6. PMC: 2997849. DOI: 10.1016/j.semcancer.2010.09.003. View

11.

Liu X, Wang L, Zhao S, Ji X, Luo Y, Ling F . β-Catenin overexpression in malignant glioma and its role in proliferation and apoptosis in glioblastma cells. Med Oncol. 2010; 28(2):608-14. DOI: 10.1007/s12032-010-9476-5. View

12.

Schneider G, Filipek A . S100A6 binding protein and Siah-1 interacting protein (CacyBP/SIP): spotlight on properties and cellular function. Amino Acids. 2010; 41(4):773-80. DOI: 10.1007/s00726-010-0498-2. View

13.

Packham G, Stevenson F . Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology. 2005; 114(4):441-9. PMC: 1782118. DOI: 10.1111/j.1365-2567.2005.02117.x. View

14.

Decker T, Hipp S, Ringshausen I, Bogner C, Oelsner M, Schneller F . Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood. 2002; 101(1):278-85. DOI: 10.1182/blood-2002-01-0189. View

15.

Damle R, Calissano C, Chiorazzi N . Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol. 2010; 23(1):33-45. PMC: 2921990. DOI: 10.1016/j.beha.2010.02.001. View

16.

Malek S . The biology and clinical significance of acquired genomic copy number aberrations and recurrent gene mutations in chronic lymphocytic leukemia. Oncogene. 2012; 32(23):2805-17. PMC: 3676480. DOI: 10.1038/onc.2012.411. View

17.

Razavi R, Gehrke I, Gandhirajan R, Poll-Wolbeck S, Hallek M, Kreuzer K . Nitric oxide-donating acetylsalicylic acid induces apoptosis in chronic lymphocytic leukemia cells and shows strong antitumor efficacy in vivo. Clin Cancer Res. 2010; 17(2):286-93. DOI: 10.1158/1078-0432.CCR-10-1030. View

18.

Zhu D, Zhu W, Fang C, Fan L, Zou Z, Wang Y . miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 2012; 33(7):1294-301. DOI: 10.1093/carcin/bgs179. View

19.

Chen X, Mo P, Li X, Zheng P, Zhao L, Xue Z . CacyBP/SIP protein promotes proliferation and G1/S transition of human pancreatic cancer cells. Mol Carcinog. 2011; 50(10):804-10. DOI: 10.1002/mc.20737. View

20.

Ning X, Sun S, Hong L, Liang J, Liu L, Han S . Calcyclin-binding protein inhibits proliferation, tumorigenicity, and invasion of gastric cancer. Mol Cancer Res. 2008; 5(12):1254-62. DOI: 10.1158/1541-7786.MCR-06-0426. View